Clinical Trials
4 trialsNCT04845035 2024-02-22
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT03838692 2021-10-13
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Columbia University
Phase 2 Withdrawn
NCT02829840 2017-06-02
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT01888562 2015-12-18
Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
Washington University School of Medicine
Phase NA Withdrawn